Meiji Holdings Co (JP:2269) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Meiji Holdings Co. subsidiary Meiji Seika Pharma Co., Ltd. has obtained approval in Japan for a partial amendment to manufacture and market its self-amplifying mRNA COVID-19 vaccine, KOSTAIVE®, tailored to the Omicron subvariant JN.1. The vaccine, which has demonstrated a strong immune response and good tolerability in clinical trials, is slated for distribution in the upcoming 2024/2025 season in a 16-dose vial format. This development is not expected to affect the company’s consolidated earnings forecast for the fiscal year ending March 2025.
For further insights into JP:2269 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue